Zoetis Inc. (ZTS)
- Previous Close
149.56 - Open
149.24 - Bid 149.00 x 800
- Ask 150.98 x 1100
- Day's Range
148.75 - 151.74 - 52 Week Range
144.80 - 201.92 - Volume
3,574,914 - Avg. Volume
3,376,598 - Market Cap (intraday)
68.944B - Beta (5Y Monthly) 0.85
- PE Ratio (TTM)
29.76 - EPS (TTM)
5.07 - Earnings Date May 2, 2024
- Forward Dividend & Yield 1.73 (1.16%)
- Ex-Dividend Date Apr 18, 2024
- 1y Target Est
218.13
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.
www.zoetis.com14,100
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: ZTS
Performance Overview: ZTS
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ZTS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ZTS
Valuation Measures
Market Cap
68.34B
Enterprise Value
73.06B
Trailing P/E
29.50
Forward P/E
25.97
PEG Ratio (5yr expected)
2.57
Price/Sales (ttm)
8.09
Price/Book (mrq)
13.68
Enterprise Value/Revenue
8.55
Enterprise Value/EBITDA
19.93
Financial Highlights
Profitability and Income Statement
Profit Margin
27.43%
Return on Assets (ttm)
13.15%
Return on Equity (ttm)
49.82%
Revenue (ttm)
8.54B
Net Income Avi to Common (ttm)
2.34B
Diluted EPS (ttm)
5.07
Balance Sheet and Cash Flow
Total Cash (mrq)
2.04B
Total Debt/Equity (mrq)
137.01%
Levered Free Cash Flow (ttm)
1.28B
Research Analysis: ZTS
Company Insights: ZTS
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: ZTS
Analyst Report: Zoetis Inc.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
RatingPrice TargetAnalyst Report: Zoetis Inc
Zoetis Inc., a 2013 spinoff from Pfizer, focuses on the development, manufacture and commercialization of animal health vaccines and medicines, including parasiticides, anti-infectives, and medicated feed additives. The company develops products for both livestock and companion animals, and distributes its products globally. Zoetis is a component of the S&P 500 and has roughly 14,100 employees.
RatingPrice TargetMarket Digest: ITRI, MU, ZTS
Inflation Taps the Market on the Shoulder
Weekly Stock List
We see what we believe are some great opportunities right now in Healthcare -- and we like the sector overall. Argus Director of Research Jim Kelleher, CFA, recently completed his quarterly sector review and raised Healthcare sector to Over-Weight from Market-Weight. The healthcare environment is undergoing rapid transitions, and we now see an unfolding period of significant promise and opportunity. Our newly-favored stance is based on resumption of deferred medical procedures and significant new quality-of-life drugs and treatments. The category is broad and has underperformed the S&P 500 over the past year. The Healthcare sector ETF (XLV) is up 15% over the past year compared to a gain of 31% for the S&P 500. We see opportunity here to pick up some steady companies, with big brands and solid financials. These companies are science-focused and enhance lives. They are innovators. In our list this week, we look across several subsectors within the Healthcare sector and pull out some leaders we like. These stocks also are included in our Focus List and Model Portfolios, as noted below.